

No Known Mutations

IRB#9902
Nivolumab or
Nivolumab +
Ipilimumab in
Advanced or
Metastatic Solid
Tumors

[IRB#11688](#)
[LOXO-101 in](#)
[Adult Patients](#)
[with Solid](#)
[Tumors](#)

IRB#11804
Lenvatibib +
Keytruda in
Subjects with
Solid Tumors

IRB# 17521
[SNDX-6352 with or](#)
[without](#)
[Durvalumab in](#)
[Patients with](#)
[Unresectable,](#)
[Recurrent, Locally-](#)
[Advanced, or](#)
[Metastatic Solid](#)
[Tumors](#)

[IRB# 18118](#)
[Study of](#)
[BA3011 in](#)
[patients with](#)
[advanced solid](#)
[tumors](#)

[IRB# 18303](#)
[Study of](#)
[Tisotumab](#)
[Vedotin for](#)
[Locally](#)
[Advanced or](#)
[Metastatic](#)
[Disease in Solid](#)
[Tumors](#)

[IRB# 18498](#)
[Study of](#)
[BA3021 in](#)
[patients with](#)
[advanced solid](#)
[tumors](#)

[IRB# 19277 A Phase 1b](#)
[Study of ASP1948,](#)
[Targeting an Immune](#)
[Modulatory](#)
[Receptor, as a Single](#)
[Agent and in](#)
[Combination with](#)
[Nivolumab in Subjects](#)
[with Advanced Solid](#)
[Tumors](#)

[IRB# 19388 A Phase 1b](#)
[Dose-Escalation Study](#)
[of Cabozantinib \(XL184\)](#)
[Administered Alone or](#)
[in Combination with](#)
[Atezolizumab to](#)
[Subjects with Locally](#)
[Advanced or Metastatic](#)
[Solid Tumors](#)

No Known Mutations

IRB 21194 study
A phase 1 study
of SGN-CD228A
in select
advanced solid
tumors

IRB# 21508
[Study of ORIC-](#)
[101 in](#)
[Combination](#)
[With Anticancer](#)
[Therapy](#)

IRB# 21464
A Study of mRNA-2752
for Intratumoral Injection
Alone and in Combination
with Immune Checkpoint
Blockade

IRB# 21766
A Phase I/Ib study of GEN-001 in
Combination with Avelumab in
Patients with Advanced Solid Tumors
Who Have Progressed during or after
Treatment with Anti-PD-(L)1 therapy


IRB# 22082 coming soon

IRB# 22797 coming soon

Key

-  Open for Enrollment
-  In Development
-  Enrollment on Hold

Note: Other Phase 1 Studies may be open at the Knight, please click here to view



Key

- Open for Enrollment
- In Development
- Enrollment on Hold

<p>P53 Y220C mutations</p>	<p>No known mutation, phase 1; TREM1 expression phase 2</p>	<p>Locally-advanced or metastatic solid tumor with an NRG1 gene fusion</p>	<p>Solid Tumors likely to express ROR1</p>	<p>Solid Tumor likely responsive to immune checkpoint inhibitors and solid tumors with a KRASG12 mutation</p>
<p>IRB 21998 coming soon</p>	<p>IRB 22223 coming soon</p>	<p>IRB 22580 coming soon</p>	<p>IRB 22680 coming soon</p>	<p>IRB 22798 coming soon</p>

Key

- Open for Enrollment
- In Development
- Enrollment on Hold